Posted by admin
Sublutiamine, 30 grams Sulbutiamine is a precursor to thiamine (i.e., vitamin B1). It has been known to help reduce fatigue and improve memory. It has also been shown to speed up reaction time, decrease anxiety, and increase overall resistance to stress. Suggested Use: 200mg 1-2 times daily. These powders are reduced down from kilo sizes. Each powder is put into a HDPE container, Heat Sealed, and labeled with dosing based off 1/4 tsp Some items may be hygroscopic and may clump during shipment. This does not effect the efficacy of the product, but just the texture.
Read the rest of this entry »
Posted by admin
Pharmacologic and therapeutic features of sulbutiamine.
Drugs Today (Barc). 1999 Mar;35(3):187-92
Authors: Van Reeth O
Asthenia is the most frequent medical reason for people seeking help from their physician. In 75% of cases, the cause is functional (either reactive or psychiatric) and in 25% it is organic. In order to provide patients with rapid relief of symptoms, appropriate antiasthenic treatment should be initiated immediately, while at the same time, adequate clinical and laboratory assessments should be performed to detect the underlying cause of asthenia. Sulbutiamine, a highly lipophilic thiamine derivative, is the only antiasthenic compound known to cross the blood-brain barrier and to be selectively active on specific brain structures directly involved in asthenia. This article reviews the current knowledge on the effects of sulbutiamine in animal models and in various forms of human asthenia.
PMID: 12973384 [PubMed]
Read the rest of this entry »
Posted by admin
Evidence for a modulatory effect of sulbutiamine on glutamatergic and dopaminergic cortical transmissions in the rat brain.
Neurosci Lett. 2000 Sep 29;292(1):49-53
Authors: Trovero F, Gobbi M, Weil-Fuggaza J, Besson MJ, Brochet D, Pirot S
Chronic treatment of rats by sulbutiamine induced no change in density of N-methyl-D-aspartate (NMDA) and (+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors in the cingular cortex, but a significant decrease of the kainate binding sites, as measured by quantitative autoradiography. In the same treated animals, an increase of D1 dopaminergic (DA) binding sites was measured both in the prefrontal and the cingular cortex, while no modification of the D2 binding sites was detected. Furthermore, an acute sulbutiamine administration induced a decrease of kainate binding sites but no change of the density of D1 and D2 DA receptors. Acute sulbutiamine injection led to a decrease of the DA levels in the prefrontal cortex and 3,4-dihydroxyphenylacetic acid levels in both the cingular and the prefrontal cortex. These observations are discussed in terms of a modulatory effect of sulbutiamine on both dopaminergic and glutamatergic cortical transmissions.
PMID: 10996447 [PubMed - indexed for MEDLINE]
Read the rest of this entry »
Posted by admin
Adjuvant role of vitamin B analogue (sulbutiamine) with anti-infective treatment in infection associated asthenia.
J Assoc Physicians India. 2003 Sep;51:891-5
Authors: Shah SN,
AIMS OF THE STUDY: Asthenic symptoms such as weakness accompany illness. This study investigates whether the centrally acting cholinergic agent, vitamin B analogue (sulbutiamine), is effective and acceptable in relieving these symptoms in infectious disease when combined with specific anti-infective treatment. METHODOLOGY: In a prospective uncontrolled, non-randomised, commercial, observational study, 1772 patients with an infectious disease and asthenic symptoms, drawn from the practice of 350 randomly selected physicians throughout India, received vitamin B analogue (sulbutiamine) in addition to specific anti-infective treatment for 15 days. The primary outcome variable was complete resolution of asthenic symptoms with treatment. RESULTS: The number (%, 95% confidence interval) of patients with complete resolution of all asthenic symptoms was 916 (51.7, 49.4-54). In the remaining patients, severe asthenia was reduced but persisted in 11 (0.6, 0-26); and moderate asthenia in 94 (5.3, 0-17.6). The response was greater in patients with acute infection and symptoms more related to cerebral function. Side effects occurred in 10 (0.6%), patients and well being improved significantly. CONCLUSIONS: Vitamin B analogue (sulbutiamine) may be a useful adjunct to specific anti-infective treatment.
PMID: 14710977 [PubMed - indexed for MEDLINE]
Read the rest of this entry »
Posted by admin
[Clinical efficacy of the drug enerion in the treatment of patients with psychogenic (functional) erectile dysfunction]
Urologiia. 2005 Jan-Feb;(1):32-5
Authors: Dmitriev DG, Gamidov SI, Permiakova OV
Twenty patients with psychogenic erectile dysfunction received the drug enerion (Hungary). After a 30-day course of enerion erectile function improved in 16 of the above patients. A mean value of the international index of erectile function (IIEF) increased in them from 17.5 to 24.8 points. Improvement of cavernous arterial blood flow after the treatment was seen in 3 of 6 patients with arterial disorders. As shown by electromyographic examinations, cavernous electric activity normalized in 8 patients. Thus, psychogenic erectile dysfunction can be effectively treated with enerion.
PMID: 15776829 [PubMed - indexed for MEDLINE]
Read the rest of this entry »
Posted by admin
[Effects of the association of sulbutiamine with an acetylcholinesterase inhibitor in early stage and moderate Alzheimer disease]
Encephale. 2007 Mar-Apr;33(2):211-5
Authors: Ollat H, Laurent B, Bakchine S, Michel BF, Touchon J, Dubois B
The efficacy of the inhibitors of acetylcholinesterase in Alzheimer’s Disease (AD) is moderated and some patients do not respond to these treatments. Sulbutiamine potentializes cholinergic and glutamatergic transmissions, mainly in hippocampus and prefrontal cortex. This multicentric, randomized and double-blind trial evaluates the effects of the association of sulbutiamine to an anticholinesterasic drug in cognitive functions in patients with AD at an early stage (episodic memory, working memory, executive functions, attention). Patients had first donepezil (D) or sulbutiamine (S) during three months. During this period, only attention improved in both groups. During the three following months, a placebo (P) in patients D and donepezil in patients S were added. Compared to entry results, episodic memory decreased in group D + P but improved in group S + D. At the same time the improvement of attention persisted in both groups. Daylife activities only improved in group S + D. In conclusion sulbutiamine can be an adjuvant to treatment in early stage and moderate AD by anticholinesterasic drugs.
PMID: 17675917 [PubMed - indexed for MEDLINE]
Read the rest of this entry »
Posted by admin
Chronic treatment with sulbutiamine improves memory in an object recognition task and reduces some amnesic effects of dizocilpine in a spatial delayed-non-match-to-sample task.
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):928-35
Authors: Bizot JC, Herpin A, Pothion S, Pirot S, Trovero F, Ollat H
The effect of a sulbutiamine chronic treatment on memory was studied in rats with a spatial delayed-non-match-to-sample (DNMTS) task in a radial maze and a two trial object recognition task. After completion of training in the DNMTS task, animals were subjected for 9 weeks to daily injections of either saline or sulbutiamine (12.5 or 25 mg/kg). Sulbutiamine did not modify memory in the DNMTS task but improved it in the object recognition task. Dizocilpine, impaired both acquisition and retention of the DNMTS task in the saline-treated group, but not in the two sulbutiamine-treated groups, suggesting that sulbutiamine may counteract the amnesia induced by a blockade of the N-methyl-D-aspartate glutamate receptors. Taken together, these results are in favor of a beneficial effect of sulbutiamine on working and episodic memory.
PMID: 15951087 [PubMed - indexed for MEDLINE]
Read the rest of this entry »
Posted by admin
[The use of enerion in the treatment of asthenic disorders in patients after mild cranio-cerebral trauma]
Zh Nevrol Psikhiatr Im S S Korsakova. 2007;107(5):44-8
Authors: Levin OS, Slizkova IuB
Asthenia is a key symptom of posttraumatic disorders (postcommotion syndrom). The dynamics of the symptom developing after mild cranio-cerebral trauma was studied during the treatment of 36 patients with enerion (20 patients) and piracetam (16 patients - control group). The authors present the results of the complex study, which includes neuropsychological tests and scales. It was shown that enerion was more effective as compared with paracetam.
PMID: 18379496 [PubMed - indexed for MEDLINE]
Read the rest of this entry »
Posted by admin
[The use of sulbuthiamine (enerion) in the combined therapy of patients with symptomatic focal epilepsy]
Zh Nevrol Psikhiatr Im S S Korsakova. 2006;106(12):68-70
Authors: Litvinovich EF, Langeman TI, Litvinovich SF
PMID: 17274400 [PubMed - indexed for MEDLINE]
Read the rest of this entry »
